Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the BoardMr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total RevenueBoard Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive ...

Core Insights - Jazz Pharmaceuticals is showcasing its advancements in oncology research at two major conferences: the 2024 San Antonio Breast Cancer Symposium (SABCS) and the 66th Annual American Society of Hematology (ASH) Annual Meeting [1][3] - The company will present significant data on its drug Ziihera® (zanidatamab-hrii), which has recently received FDA approval for treating HER2-positive biliary tract cancer [3][10] - Jazz is committed to improving treatment outcomes for patients with challenging HER2-positive cancers through ongoing clinical trials [3][9] SABCS Presentations - Jazz will present a trial-in-progress poster for the Phase 3 EmpowHER303 trial, comparing zanidatamab with trastuzumab in patients with metastatic HER2-positive breast cancer [2] - A spotlight presentation will feature new data from a Phase 1b/2 study of zanidatamab combined with evorpacept in patients with pre-treated HER2-positive and HER2-low metastatic breast cancer [2] ASH Presentations - At ASH 2024, Jazz will highlight 13 abstracts focusing on oncology research, emphasizing its dedication to enhancing standards of care in blood cancers and hematologic diseases [3] - Key presentations will include a randomized comparison of Vyxeos® (daunorubicin and cytarabine) in high-risk acute myeloid leukemia patients [4][25] Ziihera® Overview - Ziihera is a bispecific HER2-directed antibody that targets two extracellular sites on HER2, leading to tumor growth inhibition and cell death [8] - The drug is indicated for adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer, with FDA approval based on overall response rates [8][10] Development and Designations - Ziihera has received Breakthrough Therapy designation for HER2 gene-amplified biliary tract cancer and Fast Track designations for other indications [10] - The drug is being developed in collaboration with BeiGene, under license from Zymeworks, and is part of a broader clinical program aimed at solid tumors expressing HER2 [9][10]

Shares of Jazz Pharmaceuticals (JAZZ) have gained 11.5% over the past four weeks to close the last trading session at $122.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $177.06 indicates a potential upside of 44.4%.The average comprises 18 short-term price targets ranging from a low of $120 to a high of $230, with a standard deviation of $31.55. While the lowest estimate i ...

Jazz Pharmaceuticals (JAZZ) announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will be marketed under the trade name Ziihera.With this nod, Ziihera gets approved for use in previously treated adult patients with unresectable or metastatic HER2-positive BTC. The approval also makes this drug the first dual HER2-targeted bispecific antibody and chemotherapy-free therapy for treating BTC in th ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-an ...

Group 1 - The stock of Jazz Pharmaceuticals PLC (JAZZ) is experiencing significant attention due to high implied volatility in the options market, particularly for the Dec 20, 2024 $65.00 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in Jazz's stock price, potentially due to an upcoming event [2] - Jazz Pharmaceuticals holds a Zacks Rank 2 (Buy) in the Medical - Drugs industry, which is in the top 24% of the Zacks Industry Rank, indicating a generally positive outlook [3] Group 2 - Over the past 60 days, there has been a mixed sentiment among analysts regarding Jazz's earnings estimates, with two analysts raising their estimates while five have lowered them, resulting in a decrease in the Zacks Consensus Estimate from $6.03 to $5.84 per share [3] - The high implied volatility may present trading opportunities, as options traders often seek to sell premium on options with elevated implied volatility, aiming to benefit from the decay of option value [4]

Jazz Pharmaceuticals (JAZZ) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Th ...

Shares of Jazz Pharmaceuticals (JAZZ) have gained 8.9% over the past four weeks to close the last trading session at $127.74, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $175.83 indicates a potential upside of 37.7%.The average comprises 18 short-term price targets ranging from a low of $113 to a high of $230, with a standard deviation of $33.34. While the lowest estimate in ...

Have you assessed how the international operations of Jazz Pharmaceuticals (JAZZ) performed in the quarter ended September 2024? For this drugmaker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For inv ...

Core Viewpoint - Jazz Pharmaceuticals reported strong third-quarter 2024 earnings, exceeding expectations with adjusted earnings of $6.61 per share, a 37% increase year over year, and total revenues of $1.05 billion, up 9% year over year, driven by sales of Xywav and Epidiolex [1][4]. Financial Performance - Adjusted earnings per share were $6.61, surpassing the Zacks Consensus Estimate of $5.47 [1]. - Total revenues reached $1.05 billion, beating the Zacks Consensus Estimate of $1.04 billion [1]. - Net product sales increased by 5% year over year to $989.7 million, exceeding estimates of $976 million and $971 million [4]. - Royalty revenues from high-sodium oxybate authorized generic (AG) were $58.2 million, doubling from the previous year and beating the Zacks Consensus Estimate of $57 million [4]. - Other royalties and contract revenues rose 47% to $7.1 million [5]. Segment Performance - Neuroscience segment sales rose 4% to $702.7 million [6]. - Combined sales of Xyrem and Xywav fell 2% to $446.6 million, but this figure beat estimates of $431 million [6]. - Xywav sales increased 17% year over year to $388.5 million, attributed to its uptake in narcolepsy and idiopathic hypersomnia [7]. - Epidiolex/Epidyolex sales rose 18% to $251.6 million, driven by geographic expansion [8]. - Oncology segment sales increased 9% to $284.8 million, with Rylaze/Enrylaze sales at $98.8 million, down 6% year over year [9][10]. Operating Costs - Adjusted SG&A expenses rose 6% year over year to $288.7 million due to increased employee compensation [11]. - Adjusted R&D expenses decreased 17% to $181 million, primarily due to lower clinical program costs [11]. 2024 Guidance - Total revenues are projected to be between $4 billion and $4.1 billion, with the Oncology franchise expected to generate $1.08 billion to $1.13 billion, revised down from previous guidance [12]. - Neuroscience sales guidance remains at $2.83 billion to $2.93 billion, including over $200 million in royalty revenues from high-sodium oxybate AG [13]. - Adjusted earnings per share guidance has been raised to $19.50-$20.60, up from $19.20-$20.30 [13]. - Adjusted SG&A expenses are maintained at $1.19 billion to $1.23 billion, while adjusted R&D expenses are expected to be between $790 million and $830 million, revised down from $810 million to $850 million [14].